Portfolio
The Cumulus model sees multiple spin-out biotech companies founded and built, with initial capital and biotech management expertise provided by Cumulus. The first two are already successfully launched, with key milestones achieved. Additional companies are under development based on key data milestones. Company incorporation accompanies capital allocation from Cumulus.
Cumulus holds a substantial founding share in each company it establishes, fuelling our strong commitment to nurture and expedite their development.
Developing next-generation DDR-targeting therapies
Improving clinical outcomes for patients by targeting the DNA damage repair system. Exploiting our knowledge of vulnerabilities in specific subsets of cancer we are generating precision medicines to target both the primary tumour and resistance mechanisms.
Harnessing the therapeutic potential of GPCRs
Developing proprietary preclinical and clinical datasets and harnessing structural biology and cryo-EM enabling technology platforms to target key biological pathways in oncology and inflammation.
NuanBio
Developing antibodies against novel tumour targets
Antibodies and ADCs: Disrupting tumour metablism and distinct signalling pathways through targeting novel antigens that are present in multiple tumour types, through development of biologic therapeutics.
NewCo 4
Targeting untreated subpopulations within GTPases
Harnessing Molecular Simulations to develop new drugs for untreated subpopulations of cancer patients.
View our innovation pipeline
